Accessibility navigation


The use of mesenchymal stromal cells in treatment of lung disorders

Kardia, E., Zakaria, N., Halim, N. S. S. A., Widera, D. and Yahaya, B. H. (2017) The use of mesenchymal stromal cells in treatment of lung disorders. Regenerative Medicine, 12 (2). pp. 2013-2016. ISSN 1746-076X

[img]
Preview
Text - Accepted Version
· Please see our End User Agreement before downloading.

514kB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.2217/rme-2016-0112

Abstract/Summary

The therapeutic use of mesenchymal stromal cells (MSCs) represents a promising alternative clinical strategy for treating acute and chronic lung disorders. Several pre-clinical reports demonstrated that MSCs can secrete multiple paracrine factors and that their immunomodulatory properties can support endothelial and epithelial regeneration, modulate the inflammatory cascade, and protect lungs from damage. The effects of MSC transplantation into patients suffering from lung diseases should be fully evaluated through careful assessment of safety and associated risks, which is a prerequisite for translation of pre-clinical research into clinical practise. In this article we summarise the current status of pre-clinical research and review initial MSC-based clinical trials for treating lung injuries and lung disorders.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:68628
Publisher:Future Medicine

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation